Project description
Novel nanobodies help treatment target cancer cells over healthy ones
Cancer is a heterogeneous family of diseases, and accordingly, the treatments available are many and varied. They include surgery, radiotherapy and chemotherapy, immunotherapy, targeted drug therapy, and more recently, photodynamic therapy (PDT). However, no single therapy is successful across the board. PDT is one of the simplest interventions, with few and mild complications. A photosensitising agent injected into the bloodstream is absorbed by all cells, but remains in cancer cells longer. Once the agent has cleared from healthy cells, light of a specific wavelength is used to activate the agent and kill cancer cells. The EU-funded READY project targets the photosensitisers directly to cancer cells, killing tumours while also boosting the immune system for long-term protection. The team is now developing a path to market.
Objective
Unfortunately, current cancer therapies often fail to cure patients, or are associated with severe side effects. Ideally, a therapy should locally eradicate cancer cells without damaging healthy tissue and should induce long term protection through activation of the immune system. Photodynamic therapy (PDT) is a treatment approach which can do both, through the local light activation of photosensitizers. However, current photosensitizers lack cancer specificity, which limits therapeutic efficacy and prolongs photosensitivity in patients.
Recently, Dr. Oliveira has developed an improved version of targeted PDT that uses small antibody fragments, i.e. nanobodies, to target the photosensitizer to cancer cells. Nanobodies distribute homogenously, bind rapidly and specifically to cancer cells, and are quickly eliminated when unbound. Within the ERC StG KILLCANCER project, the team has been focusing on better understanding the mechanism of nanobody-targeted PDT, its potential to induce tumor regression in vivo, and its capacity to trigger the immune system for long term protection. Results indicate this treatment could lead to improved selectivity and reduced side effects, compared to conventional PDT and antibody-targeted PDT.
The fundamental objective of this ERC PoC is to ascertain the technical and commercial viability of nanobody-targeted PDT for treatment of head and neck cancer. Within this project, the aims are to:
1. Humanize the lead nanobody, validate the results, and explore GMP production
2. Perform an IP landscape analysis and establish freedom-to-operate (FTO)
3. Execute an extensive market, competitor, and stakeholder analysis, and
4. Develop a detailed business plan based on this information to accurately guide commercialisation.
Together, these steps will be essential for nanobody-targeted PDT to be ready for the translation to humans, so that cancer patients and society as a whole can benefit from this promising alternative treatment.
Fields of science
Keywords
Programme(s)
Funding Scheme
ERC-POC - Proof of Concept GrantHost institution
3584 CS Utrecht
Netherlands